

Over 25 million **optomap**® exams have been performed worldwide, helping us to secure our leading position in retinal diagnostics

Key Statistics


(figures in \$US)

H1-10 Highlights

Revenue from PPP contracts	\$45.4m
Total Revenue	\$47.3m
Gross profit	\$31.2m
Operating profit	\$4.3m
Profit after tax	\$1.5m
EPS diluted (cents)	2.1c
Cash flow from operating activities	\$21.6m
Net debt	(\$32.7m)

(cash less lease finance liabilities)

- \$170m of future revenues secured under contracts




Company Overview

Optos plc is an innovative retinal imaging company with a vision to be recognised as the leading provider of retinal diagnostics.

The retina provides a unique view of the health of a patient enabling both eye and systemic diseases to be diagnosed. An **optomap** exam can lead to early detection of common diseases such as glaucoma, diabetes and macular degeneration.

The **optomap** exam is the only eye exam that provides an ultra-widefield 82% view of the retina and does so in just 0.25 seconds.

The **optomap** image is displayed immediately enabling eye doctors to promptly diagnose problems and its digital format allows the eye specialist to send the image anywhere in the world for expert review if necessary. This is why more than 12,000 people per day choose to have an **optomap**.



The **optomap** exam captures nearly the whole of the retina in one step compared to the small view seen by conventional equipment

Business Models

- Devices are usually installed on 3-year pay-per-patient rental agreements
- Customers typically pay a minimum monthly payment plus a variable per **optomap** fee over the minimum but can elect for a fixed monthly rental payment
- Rental customers are entitled to service, maintenance, patient support, and software and hardware upgrades
- Alternatively, customers buy the device outright and enter into service agreements covering maintenance, parts and some upgrades

Quick Facts

- Operations in UK (Dunfermline), US (Boston) and Germany
- Over 25m **optomap** exams performed to date *(as at June 2010)*
- Devices are used primarily in "wellness" market to screen and verify eye health and monitor eye and non-eye diseases
- 85% of Optos' business is in the USA, but we are growing quickly in Europe
- 95% of Optos' revenue is from the core optometry sector
- Optos has 20% market penetration in 'target sectors' in existing markets - providing significant growth potential

Products and Customers


- Over 4,000 eye professionals have used the **optomap** technology
- Our P200 device is used as a diagnostic exam, principally by optometrists
- Our P200C device with enhanced resolution is used by certain optometrists and ophthalmologists in disease management
- Our P200MA device with additional features such as fluorescence angiography is targeted at ophthalmologists and vitreo retinal specialists as part of disease treatment regimes
- Significant advances made in our development programmes, with imminent launch of software and hardware upgrades



Strategy and Vision

To expand our channel, segments and geographic markets to secure our leading position in Retinal Diagnostics

Drive Technology Adoption	Create a lean customer focused organisation
By creating and increasing demand from insurance providers, patients and eye-care professionals, making the optomap the "gold standard" retinal diagnostic exam	Providing our customers with reliable, leading-edge technology and support is central to our strategy
Deliver value to practitioners and their customers	Exploit opportunities for future growth
By offering flexible business models, both outright capital sales or a rental option that allows access to a constantly upgraded suite of diagnostic tools, software and devices without major capital expenditure	By understanding and developing new geographic markets and adjunct technologies to enhance our offering to both optometrists and ophthalmologists



Share Information

Ticker symbol: **OPTS**


Issued share capital: **70,421,475 (as at 1 June 2010)**

Top shareholding (as at 1 June 2010)

Amadeus Funds (inc Anne Glover)	19%
Patrick Paul (inc Chester Investments)	7.26%
Douglas Anderson (inc Crombie Anderson)	3.93%

Analyst coverage

Goldman Sachs	Veronika Dubajova
Piper Jaffray	Julie Simmonds
Nomura Code	Gary Waanders
Brewin Dolphin	Chris Glasper
Edison	John Savin
Panmure Gordon	Damian McNeela
Singer CM	Elizabeth Klein



Optos plc is followed by these analysts. Any opinions, estimates or forecasts regarding Optos plc and its performance made by these analysts is theirs alone and do not necessarily represent opinions, forecasts or predictions of Optos plc or its management. The company does not endorse the views and conclusions of these firms or the reports issued by their analysts.

The Optos Team

Roy Davis	Chief Executive Officer
Christine Soden	Chief Financial Officer
Mike Geraghty	Executive VP Global Sales
Tom Daniells	VP Global Corp Accounts & Business Dev.
Tom Motta	VP Global Operations
Alex Warnock	VP Global R&D
Robert Tweedlie	VP Global Quality Assurance & Regulatory Affairs
Douglas Anderson	Founder & VP Global Advocacy

Contacts

Optos plc
Queensferry House, Carnegie Business Campus
Dunfermline
Scotland KY11 8GR
United Kingdom

Switchboard: + 44 (0) 1383 843 300
Email: ir@optos.com
Visit www.optos.com for our worldwide locations.